Matthias König: Developing an Open Whole-Body PBPK/PD Digital Twin of Apixaban
Matthias König, Associate Professor of Pharmacoepidemiology and Data Science at University of Southern Denmark, shared a post on LinkedIn about a recent preprint, he and his colleagues co-authored, published in Preprints.org, adding:
“New preprint: ‘An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics.’
In this work, we developed an open whole-body PBPK/PD digital twin of the direct oral anticoagulant apixaban, linking drug exposure to anticoagulation-related pharmacodynamic endpoints, including INR, PT, mPT, aPTT, and anti-Xa activity.
The model was built and evaluated using data from 35 curated clinical PK/PD studies, covering diverse dosing regimens and clinically relevant scenarios, including renal and hepatic impairment, food intake, and body weight effects.
It captures apixaban pharmacokinetics and pharmacodynamics across these populations and provides a reusable framework for personalised anticoagulant therapy.
A key focus was reproducibility and openness: all models, simulation workflows, documentation, and curated datasets are openly available and FAIR-compliant, enabling transparent reuse, independent verification, and future extension.
The work was developed as part of the Berlin University Alliance (BUA) X-Student Research Group ‘Digital Twins in Action:
Optimizing Direct Oral Anticoagulant Use’, funded by the Bundesministerium für Bildung und Forschung (BMBF) and the State of Berlin as part of the Excellence Strategy of the Federal and State Governments.”
Title: An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics
Authors: Mariia Myshkina, Mariia Babaeva, Linh Chang Nguyen, Shelee Bedón, Johannes Metternich, Michelle Elias, Matthias König
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC